Last Updated: November 13, 2026

Litigation Details for Lexmark International, Inc. v. Ink Technologies Printer Supplies, LLC (S.D. Ohio 2010)

« Back to Dashboard


Small Molecule Drugs cited in Lexmark International, Inc. v. Ink Technologies Printer Supplies, LLC
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Lexmark International v. Ink Technologies (1:10-cv-00564): Litigation Summary, Claims, Posture, and IP/Commercial Impact

Last updated: July 28, 2026

Lexmark International, Inc. v. Ink Technologies Printer Supplies, LLC (D. Maryland, 1:10-cv-00564) is a trademark/trade-dress and related consumer-product IP dispute centered on printer-ink/cartridge replacement sales and the scope of Lexmark’s rights in connection with those products. The litigation record and outcomes that are necessary to produce a complete, citation-grade summary and analysis are not present in the information provided here, so a complete response cannot be generated.

What is Lexmark International v. Ink Technologies Printer Supplies (1:10-cv-00564) about?

A complete summary requires the complaint’s asserted causes of action (for example, Lanham Act trademark claims, trademark infringement theories tied to “return/recycling” or “authorized use,” copyright/misappropriation theories, breach-of-warranty, or trade dress), the accused ink/cartridge SKUs, and the specific pleadings and orders (motions to dismiss, preliminary injunction, claim construction, summary judgment, jury verdict, or dismissal/settlement). Those elements are not included here.

What claims and legal theories did Lexmark assert in 1:10-cv-00564?

A litigation analysis typically maps each claim to (1) the factual predicate (marking, packaging, compatibility statements, channel, and remanufactured versus new replacement ink), (2) the legal elements, and (3) the remedies sought (injunction, damages, disgorgement, and attorneys’ fees). The operative pleading and orders are not provided, so the claim set and theory mapping cannot be produced accurately.

What was the procedural posture of the case (motions, discovery, trial, and final disposition)?

To summarize posture with business utility, the answer needs a procedural timeline: filing date, service, any TRO/preliminary injunction, motion practice dates (Rule 12 and Rule 56), and the final outcome date (judgment on the merits, dismissal without prejudice, settlement with or without consent judgment, or compliance-based dismissal). None of that is present here.

How does the case relate to Lexmark’s broader IP strategy for ink cartridges?

Lexmark has pursued multiple enforcement tracks across printer-ink ecosystems, including restrictions on trademark use, limitations on replacement-cartridge labeling/packaging, and channel control. A meaningful “how it compares” analysis against Lexmark’s other matters requires the factual and legal overlap (same product class, same jurisdictions, same asserted IP theories, same distribution model). Those anchors are not included here.

Did the court address “patent exhaustion” or “first sale” issues?

Because this docket number is commonly associated with ink-cartridge enforcement disputes that may touch “authorized use,” “conditional sale,” or exhaustion-like arguments, the analysis must verify whether the court ruled on exhaustion/first sale theories, and whether those rulings depended on sale conditions or contractual restrictions. The order text or holdings are not provided.

What was the remedy and how did it affect Lexmark versus Ink Technologies?

A remedy-focused business impact analysis needs the final relief terms (injunction scope, redesign/labeling requirements, account takedowns, destruction obligations, monetary damages or fee awards, and duration). These are not provided.

What does the case imply for future Paragraph IV–style challenges and FDA-type exclusivity, if any?

This question is not applicable to printer-ink litigation in the same way it applies to pharmaceutical exclusivity or Orange Book/ANDA matters. Converting it into a relevant printer-ink analogue would still require the actual legal issues and holdings from the docket record, which are not provided.

How strong was Lexmark’s patent estate in this litigation?

This is not a patent-only case summary unless patents were asserted. A correct answer requires listing asserted patents (if any), their claims, validity challenges, and infringement findings. No such information is included here.

Key Takeaways

No complete, accurate litigation summary or analysis can be generated from the information provided.

FAQs

  1. What causes of action were asserted in Lexmark International v. Ink Technologies Printer Supplies (1:10-cv-00564)?
  2. What court orders shaped the case outcome (injunction, dismissal, or settlement)?
  3. Did the court rule on trademark “use in commerce” and likelihood of confusion theories?
  4. Were exhaustion or first-sale doctrines raised, and did the court address them?
  5. What remedy terms did the final disposition impose on Ink Technologies’ ink/cartridge sales?

References

(0)

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.